Currently, there is a dearth of reliable diagnostic and prognostic markers for MS (the utility of serum neurofilament light (sNfL) as an MS marker remains limited),56, 57 and our findings present a novel opportunity to develop a more comprehensive panel of polygenic markers. This evidence concerns the gene NEFL and myeloid sarcoma.